Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human study of PRAX-628 in healthy adults
NL-OMON51482Phase 1Completed
- Sponsor
- Praxis Precision Medicines
- Start
- Dec 2022
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vormatrigine in Focal Onset Epilepsy (4 arms), sponsored by Praxis Precision Medicines. Started Dec 2022; status: completed.
02
Drugs
vormatrigine
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on NL-OMON51482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51482.